Elevated plasma GLP-1 levels and enhanced expression of cardiac GLP-1 receptors as markers of left ventricular systolic dysfunction: A cross-sectional study

BMJ Open

Volumn 3, Issue 9, 2013, Pages

  Hattori, Arihiro ^a   Kawamura, Itta ^a   Yamada, Yoshihisa ^a   Kanamori, Hiromitsu ^a   Aoyama, Takuma ^a   Ushikoshi, Hiroaki ^a   Kawasaki, Masanori ^a   Nishigaki, Kazuhiko ^a   Tamemura, Genzou ^a   Minatoguchi, Shinya ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; HEMOGLOBIN A1C; IMMUNOREACTIVE INSULIN;

AGED; ARTICLE; CARDIOMYOPATHY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; FEMALE; GLUCAGON BLOOD LEVEL; HEART CATHETERIZATION; HEART MUSCLE BIOPSY; HUMAN; IMMUNOHISTOCHEMISTRY; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PROTEIN EXPRESSION; VALVULAR HEART DISEASE;

EID: 84885367670     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-003201     Document Type: Article

References (25)

1. Grieve DJ, Cassidy RS, Green BD Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control? Br J Pharmacol 2009; 157:1340-51.
2. Orskov C, Rabenhøj L, Wettergren A., et al Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 1994;43:535-9. (Pubitemid 24096293)
3. Deacon CF. Circulation and degradation of GIP and GLP-1. Horm Metab Res 2004;36:761-5. (Pubitemid 40115896)
4. Knudsen LB, Pridal L. Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur J Pharmacol 1996;318:429-35. (Pubitemid 27046288)
5. Bose AK, Mocanu MM, Carr R.D., et al Glucagon-like peptide-1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005;54:146-51. (Pubitemid 40105106)
6. Ban K, Noyan-Ashraf M, Hoefer J., et al Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008;117:2340-50. (Pubitemid 351653542)
7. Timmers L, Henriques JPS, de Kleijin DP, et al Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol 2009; 53:501-10.
8. Nikolaidis LA, Mankad S, Sokos G.G., et al Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004;109:962-5. (Pubitemid 38282847)
9. Lonborg J, Veilstrup N, Kelbek H., et al Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J 2012;33:1491-9.
10. Matsubara J, Sugiyama S, Sugamura K., et al A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. J Am Coll Cardiol 2012; 59:265-76.
11. Nathanson D, Zethelius B, Berne C., et al Plasma levels of glucagon like peptide-1 associate with diastolic function in elderly men. Diabet Med 2011;28:301-5.
12. Drucker DJ. The biology of incretin hormones. Cell Metab 2006;3:153-65.
13. Ossum A, van Deurs U, Engstrom T, et al The cardioprotective and inotropic components of the postconditioning effects of GLP-1 and GLP-1(9-36)a in an isolated rat heart. Pharmacol Res 2009;60:411-17.
14. Sonne DP, Engstrom T, Treiman M. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart. Regul Pept 2008;146:243-9.
15. Iwasa M, Kobayashi H, Yasuda S., et al Anti-diabetic drug voglibose is protective against ischemia-reperfusion injury via GLP-1 receptors and PI3 kinase-Akt-eNOS pathway in rabbits. J Cardiovasc Pharmacol 2010;55:625-34.
16. Iwasa M, Yamada Y, Kobayashi H., et al Both stimulation of GLP-1 receptors and inhibition of glycogenolysis additively contribute to a protective effect of oral miglitol against ischaemia-reperfusion injury in rabbits. Br J Pharmacol 2011;164:119-31.
17. Thrainsdottir I, Malmberg K, Olsson A., et al Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure. Diab Vasc Dis Res 2004;1:40-3.
18. Sokos GG, Nikolaidis LA, Mankad S, et al Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 2006;12:694-9. (Pubitemid 44881367)
19. Wei CM, Heublein DM, Perrella M.A., et al Natriuretic peptide system in human heart failure. Circulation 2993;88:1004-9.
20. Maeda K, Tsutamoto T, Wada A., et al Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998;135:825-32. (Pubitemid 28237306)
21. Tsutamoto T, Wada A, Maeda K., et al Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997;96:509-16. (Pubitemid 27329427)
22. Nagueh SF, Appleton CP, Gillebert T.C., et al Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 2009;22:107-33.
23. Lubien E, DeMaria A, Krishnaswamy P., et al Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation 2002;105:595-601. (Pubitemid 34123434)
24. Kim M, Platt MJ, Shibasaki T, et al GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med 2013; 2013;19:567-75.
25. Bhashyam S, Fields AV, Patterson B, et al Glucagon-like peptide-1 increases myocardial glucose uptake via p38alpha MAP kinase-mediated, nitric oxide-dependent mechanisms in conscious dogs with dilated cardiomyopathy. Circ Heart Fail 2010;3:512-21. Technology